ValuEngine lowered shares of Cryolife (NYSE:CRY) from a hold rating to a sell rating in a research report report published on Wednesday morning.
Several other brokerages have also issued reports on CRY. Canaccord Genuity reaffirmed a buy rating and issued a $25.00 target price on shares of Cryolife in a research note on Wednesday, January 3rd. Northland Securities reaffirmed a buy rating and issued a $23.50 target price on shares of Cryolife in a research note on Monday, November 13th. Finally, Zacks Investment Research raised shares of Cryolife from a sell rating to a hold rating in a research note on Tuesday, January 16th. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The company has an average rating of Hold and an average price target of $25.83.
Cryolife (CRY) opened at $21.70 on Wednesday. The stock has a market cap of $739.41, a PE ratio of 217.02 and a beta of 0.75. The company has a debt-to-equity ratio of 0.29, a current ratio of 4.18 and a quick ratio of 4.90. Cryolife has a one year low of $14.02 and a one year high of $24.00.
In related news, Director C Elkins Ronald sold 2,000 shares of Cryolife stock in a transaction that occurred on Thursday, March 8th. The shares were sold at an average price of $22.00, for a total transaction of $44,000.00. Following the transaction, the director now owns 97,849 shares of the company’s stock, valued at approximately $2,152,678. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.00% of the stock is owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Teacher Retirement System of Texas bought a new position in Cryolife during the 4th quarter worth approximately $197,000. Metropolitan Life Insurance Co. NY bought a new stake in shares of Cryolife in the fourth quarter valued at about $203,000. Crossmark Global Holdings Inc. bought a new stake in shares of Cryolife in the third quarter valued at about $259,000. Stifel Financial Corp bought a new stake in shares of Cryolife in the third quarter valued at about $275,000. Finally, Hartford Investment Management Co. bought a new stake in shares of Cryolife in the third quarter valued at about $276,000. 73.99% of the stock is currently owned by institutional investors and hedge funds.
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.